Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Vascepa patents under legal scrutiny

Even if Amarin prevails in its patent infringement lawsuit, its key patents on Vascepa are likely to be ruled invalid in ongoing litigation, opening the way for generic formulations.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Curfman, G. JAMA Intern. Med. 177, 194 (2017).

    Article  Google Scholar 

  2. Manson, J. E. et al. N. Engl. J. Med. 380, 23–32 (2019).

    CAS  Article  Google Scholar 

  3. Ballantyne, C. M. et al. Am. J. Cardiol. 110, 984–992 (2012).

    CAS  Article  Google Scholar 

  4. Bays, H. E. et al. Am. J. Cardiol. 108, 682–690 (2011).

    CAS  Article  Google Scholar 

  5. Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. 033020 NVDC, 2:16-cv-02525-MMD-NJK.

  6. Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc. et al. USCAFC 20-1723, doc 70, 9-30-2020.

  7. US Food and Drug Administration. ANDA approval letter to Hikma Pharmaceuticals USA Inc., (2020).

  8. Bhatt, D. L. et al. N. Engl. J. Med. 380, 11–22 (2019).

    CAS  Article  Google Scholar 

  9. US Food and Drug Administration. Supplement approval letter to Amarin Pharma Inc., (2019).

  10. Federal Food, Drug, and Cosmetic Act, Section 505(j)(2)(A)(viii).

  11. US Food and Drug Administration. Preface, Orange Book, 42nd edn,, (2022).

  12. Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc et al. C.A. No. 20-1630-RGA-JLH; (August 2021).

  13. Amarin Pharma v. Hikma Pharm. US. C.A. 20-1630-RGA-JLH (D. Del.,, (January 2022).

  14. Silbersher, Z. Will Amarin’s new cardiovascular patent lawsuit against Hikma keep out generic sales? Markman Advisors, (December 2020).

  15. Yokoyama, M. et al. Lancet 369, 1090–1098 (2007).

    CAS  Article  Google Scholar 

  16. Nicholls, S. J. et al. J. Am. Med. Assoc. 324, 2268–2280 (2020).

    CAS  Article  Google Scholar 

  17. Gugliuzza, P. R. Iowa Law Rev. 106, 607–664 (2021).

    Google Scholar 

  18. 35 USC § 103;

  19. Graham v. John Deere Co. 383 US 1, 148 USPQ 459 (1966).

  20. KSR International Co. v. Teleflex Inc. 550 US 398, 82 USPQ2d 1385 (2007).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Gregory Curfman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Curfman, G., Cole, J. Vascepa patents under legal scrutiny. Nat Biotechnol 40, 829–831 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing